To test this hypothesis, we used the selective and reversible MAOB inhibitor KDS2010, which circumvents the shortcomings of irreversible MAOB inhibitors.12 We first evaluated the effect of KDS2010 on recovery after SCI at a dose of 10 mg/kg (mpk), which was previously reported to be effective in treating other neurological diseases.12–14 The pharmacokinetic (PK) analysis of KDS2010 was performed in mice, rats, and nonhuman primates. The gene discussed is MAOB; the disease is nervous system disorder.